Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Reporting Period: Fiscal Year Ended December 31, 2024
Operations: A Nevada holding company with all operations conducted through its wholly-owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), in the People's Republic of China (PRC). The company develops, manufactures, and markets pharmaceutical products (generic drugs, first-to-market generics, and Traditional Chinese Medicines) and healthcare products.
Stock Status: Common stock trades on NYSE American under symbol "CPHI". The company implemented a 1-for-5 reverse stock split effective March 6, 2024, and a 1-for-10 reverse split effective March 6, 2023.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $4.53 million | $7.01 million |
| Cost of Revenue | $6.51 million | $7.29 million |
| Gross Loss | $(1.99) million | $(0.28) million |
| Gross Margin | -43.8% | -4.0% |
| Operating Loss | $(4.59) million | $(2.75) million |
| Net Loss | $(4.74) million | $(3.08) million |
| Loss Per Share (Basic & Diluted) | $(0.27) | $(0.91) |
| Cash and Cash Equivalents | $0.63 million | $1.42 million |
| Total Assets | $14.89 million | $16.47 million |
| Total Liabilities | $7.14 million | $9.01 million |
| Working Capital | $(1.75) million deficit | $(0.82) million deficit |
| Debt (Lines of Credit) | $2.41 million (Total) | $2.44 million (Total) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 35.4% ($2.48 million) primarily due to the impact of China's Centralized Procurement (CP) policies. Competitors with passed consistency evaluations secured bids at lower prices, while Helpson's products (e.g., Roxithromycin) were excluded from CP due to pending evaluations.
- Margin Deterioration: Gross margin collapsed from -4.0% to -43.8%. This was driven by a significant decline in sales volume coupled with fixed costs, resulting in idle equipment costs of approximately $0.66 million and increased inventory impairment provisions of $0.86 million.
- Product Category Shifts:
- Digestive Diseases: Revenue plummeted 82% ($0.89 million) due to market normalization of Omeprazole sales post-2023 spike.
- Anti-Viral/Infection: Revenue dropped 23% ($0.82 million) as Roxithromycin failed to qualify for CP.
- CNS/Cardiovascular: Revenue declined 17% ($0.27 million) due to market fluctuations in Ozagrel Sodium sales.
- Intangible Assets: Significant increase in intangible assets (from $3.26 million to $6.70 million) due to the acquisition of multiple invention patents via technology transfer agreements, paid for through the issuance of common stock.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
- Going Concern: The auditors have issued a "substantial doubt" opinion regarding the company's ability to continue as a going concern due to recurring losses, accumulated deficit of $44.0 million, and working capital deficit. Management plans to mitigate this by enhancing advance payment sales models, accelerating the launch of nutrition products (e.g., freeze-dried bird's nest), and utilizing fixed assets as collateral for additional loans.
- Strategic Initiatives: The company is pursuing Contract Manufacturing Organization (CMO) services, which generated approximately $50,000 in 2024. It is also focusing on consistency evaluations for existing products to regain eligibility for Centralized Procurement.
- Dividends: The company does not anticipate paying cash dividends in the foreseeable future.
Risks and Contingencies
- Regulatory Risk (PRC): Operations are heavily dependent on PRC regulations, including the National Medical Products Administration (NMPA) consistency evaluations and Centralized Procurement pricing policies. Failure to pass evaluations excludes products from major government tenders.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of personnel knowledgeable in U.S. GAAP.
- Accounts Receivable: As of December 31, 2024, 98.27% of gross trade accounts receivable were aged over 720 days. The allowance for credit losses covers 98.3% of total receivables, indicating severe collection risks.
- Related Party Dependence: The company relies on advances from its CEO/Chairperson (Zhilin Li) for working capital, totaling $1.14 million as of year-end.
Investor Verification Checklist
- Going Concern Status: Verify the feasibility of management's plans to generate cash flow and secure additional financing to avoid liquidation.
- Receivables Quality: Investigate the recoverability of the $13.8 million in gross accounts receivable, 98% of which is over two years old.
- Consistency Evaluation Progress: Confirm the status of pending consistency evaluations for key products (e.g., Roxithromycin) required to participate in Centralized Procurement.
- Intangible Asset Valuation: Review the valuation and amortization schedules of the patents acquired in 2024 via stock issuance to ensure they align with future revenue potential.
- Related Party Transactions: Monitor the terms and repayment status of loans and advances from the CEO and other related parties.